<DOC>
	<DOCNO>NCT00245986</DOCNO>
	<brief_summary>This study evaluate effect genetics metabolism anti-HIV medicine efavirenz ( Sustiva ) see Efavirenz interacts bupropion ( Zyban Wellbutrin ) , drug commonly use treat depression help people quit smoke . Efavirenz metabolize enzyme call CYP2B6 , think active people others , depend genetic makeup . The rate metabolism drug affect body respond perhaps ability HIV virus develop resistance . Healthy volunteer 18 55 year age non-smokers HIV-infected men woman 18 year age old take efavirenz along two three nucleoside reverse transcriptase inhibitor may eligible study . Candidates screen medical history physical examination blood test , include test determine gene four different protein enzyme ( CYP2B6 , CYP3A4 , CYP3A5 , MDR1 ) metabolize drug . Participants assign one three group follow procedure : -HIV-infected individual : Blood sample draw measure efavirenz level , follow : On last day take efavirenz , subject skip usual even efavirenz dose night sample . The next morning clinic , catheter ( flexible plastic tube ) insert vein subject 's arm collecting blood sample . After first sample drawn , subject take dose efavirenz . Eight blood sample collect 1 , 2 , 4 , 6 , 8 , 12 , 24 48 hour take efavirenz tablet . ( The catheter remove 12-hour sample subject discharge home , return clinic 24- 48-hour sample , collect needle insert arm vein . ) The subject return clinic four time single blood draw 7 , 14 , 21 28 day stop efavirenz . HIV-infected patient whose HIV viral load reach 1,000 copies/L within 12 month complete study ask return clinic blood draw check genotype virus drug resistance . - Healthy Volunteers - Group 1 : Blood sample draw measure efavirenz level , follow : Participants take one efavirenz tablet day 13 15 day . On last day take efavirenz , subject take his/her last dose efavirenz clinic , blood collect described HIV-infected individual . - Healthy Volunteers - Group 2 : A catheter insert vein subject 's arm blood sample drawn catheter . The subject take single bupropion tablet additional blood sample draw 1,2 , 2.5 , 3 , 3.5 , 4 , 6 , 8 , 12 , 24 48 hour dose measure amount drug blood . Subjects begin take efavirenz 0 6 day last bupropion blood level measure . As , subject take one efavirenz tablet day 13 15 day . On last day take efavirenz , catheter insert subject 's arm . Two blood sample draw catheter , subject take daily dose efavirenz along bupropion tablet . Eleven additional blood sample draw 1 , 2 , 2.5 , 3 , 3.5 , 4 , 6 , 8 , 12 , 24 , 48 hour take pill measure blood level bupropion . Eight additional sample collect 1 , 2 , 4 , 6 , 8 , 12 , 24 , 48 hour measure efavirenz blood level . ( The catheter remove 12-hour sample subject discharge home ; 24- 48-hour sample collect needle inserted arm vein . )</brief_summary>
	<brief_title>Effect Genetics Metabolism Efavirenz</brief_title>
	<detailed_description>Efavirenz ( EFV ) non-nucleoside reverse transcriptase inhibitor ( NNRTI ) long half-life , allow once-daily dosing . Although generally well-tolerated widely use , major disadvantage EFV relatively low barrier resistance . The single K103N mutation confers high-level resistance EFV , well NNRTI 's . Acquisition HIV-1 resistance likely result repeat exposure virus subtherapeutic drug concentration . When terminate EFV therapy recommend EFV stop 1-2 week earlier concomitant antiretrovirals ( ARVs ) account long washout period . Alternatively , substitute EFV protease inhibitor 1 4 week also recommend . Both strategy attempt avoid prolong EFV exposure follow discontinuation concomitant ARVs , thereby lower risk acquire new resistance mutation . Though widely utilize , neither method validate pharmacokinetic clinical study . Genetic difference CYP2B6 contribute greatly observed variability EFV clearance ; hence , genetic difference may contribute significantly different response method therapy discontinuation . Multiple polymorphisms CYP2B6 identify . Substitutions position 516 , 785 , 1459 common variant , appear associate alteration CYP2B6 activity . We propose 2-part study . Part I conduct HIV-negative volunteer , consists : ( 1 ) determination EFV pharmacokinetic ( PK ) value ( follow 13-15 day EFV 600 mg/day ) comparison CYP2B6 genotype ( include wild-type allelic variant position 516 , 785 1459 ) , ( 2 ) measurement single EFV plasma concentration 7 , 14 , 21 , 28 day drug stop assess difference EFV exposure CYP2B6 genotype , ( 3 ) comparison bupropion PK value follow administration single bupropion dose ( ) prior EFV administration ( b ) 13-15 day EFV , evaluate whether EFV modulate CYP2B6 metabolism use bupropion probe CYP2B6 function . Part II conduce HIV-positive patient plan discontinue ( d/c ) EFV therapy , include : ( 1 ) determination EFV PK value prior d/c therapy comparison different CYP2B6 genotype , ( 2 ) measurement single EFV plasma concentration 7 , 14 , 21 28 day post-EFV assess difference exposure across CYP2B6 genotype , ( 3 ) genotypic evaluation HIV-1 drug resistance perform patient HIV RNA = 1,000 copies/mL , prior EFV discontinuation ( 12 month stop EFV ) , preliminary study evaluate incidence EFV resistance mutation base CYP2B6 genotype . Data study help describe relationship CYP2B6 genetic polymorphism PK variability EFV , specifically address effect prolong EFV exposure follow discontinuation therapy . In addition , study determine whether EFV modulate CYP2B6 activity assess bupropion phenotyping . Lastly , attempt provide preliminary information whether genetic variability CYP2B6 relate incidence NNRTI-resistance stop change EFV therapy .</detailed_description>
	<mesh_term>Efavirenz</mesh_term>
	<criteria>ELIGIBILITY CRITERIA : Healthy Volunteers : 1 . Males female age 18 55 year . 2 . Healthy medical history physical exam 3 . Laboratory value within establish guideline participation clinical study : AST le 1.25 x ULN ; SCr le equal ULN ; hemoglobin equal great 11 g/dL ( male female ) . 5 . ) Ability abstain eat grapefruit drinking grapefruit juice EFV administration EFV PK sample period . 6 . ) Negative serum pregnancy test female childbearing potential ( within 1 day start EFV ) . 7 . ) Females childbearing potential able willing either practice abstinence use two nonhormonal form birth control ( condom , diaphragm , IUDs , etc . ) take EFV 28th day last EFV dose . 8 . ) Nonsmokers least 1 month prior study participation . 1 . Concomitant routine therapy prescription , overthecounter , herbal , holistic medication , include oral contraceptive hormonal IUDs , 14 day prior study participation . Intermittent use acetaminophen nonsteroidal antiinflammatory medication ( i.e . ibuprofen ) allow study , take day pharmacokinetic blood sampling . Intermittent use nonsedating antihistamine fexofenadine cetirizine topical hydrocortisone cream allow study supervision approval study team ; however , fexofenadine cetirizine take day pharmacokinetic blood sampling . A daily multivitamin mineral allow study . 2 . Inability obtain venous access blood sample collection . 3 . The presence history follow : HIV infection , active tuberculosis , renal disease ( chronic acute renal failure insufficiency ) , diabetes , hepatitis B C infection ( assessed patient interview ) hepatic impairment , pancreatitis , peptic ulcer disease require maintenance pharmacologic therapy , injection drug use , epilepsy seizure disorder , history head trauma , psychiatric illness symptom ( include , limited depression , bipolar disorder , history suicide attempt suicidal ideation , psychosis , schizophrenia , bulimia anorexia nervosa ) assess patient interview clinician evaluation use Beck Depression Index , condition may interfere interpretation study result best interest subject opinion investigator . 4 . Positive pregnancy test breastfeed female . 5 . A previously document history persistent diarrhea malabsorption would interfere subject 's ability absorb drug . 6 . Drug alcohol abuse may impair safety adherence interfere study result ( 3 alcoholic drink per day regular basis ) . 7 . History intolerance allergic reaction efavirenz ( Sustiva® ( Registered Trademark ) ) bupropion ( Wellbutrin® ( Registered Trademark ) ) . HIVinfected volunteer : Inclusion Criteria 1 . HIVpositive male female least 18 year old . 2 . On standard EFVcontaining regimen ( EFV + 2 3 NRTIs ) least 1 month prior study participation . 3 . Laboratory value within establish guideline participation clinical studies53 : AST le equal 1.25 x ULN ; SCr le equal ULN ; hemoglobin equal great 11 g/dL ( male female ) . 4 . Ability abstain eat grapefruit drinking grapefruit juice EFV PK sample period 3 day prior . 5 . A negative pregnancy test woman childbearing potential . Exclusion Criteria 1 . ) Concomitant therapy PI NNRTI EFV 30 day prior study participation . 2 , ) Concomitant therapy prescription , overthecounter , herbal , holistic medication know interact EFV modulate CYP2B6 activity 14 day prior study participation . 3 . ) Inability obtain venous access blood sample collection . 4 . ) The presence follow : Any active opportunistic infection ( include , limited tuberculosis , Mycobacterium avium complex , cytomegalovirus , Pneumocystis jiroveci , Cryptococcus neoformans , esophageal candidiasis ) , renal disease ( chronic acute renal failure insufficiency ) , hepatic impairment , pancreatitis , condition may interfere interpretation study result best interest subject opinion investigator . 5 . ) A previously document history persistent diarrhea malabsorption would interfere subject 's ability absorb drug . 6 . ) Drug alcohol abuse may impair safety adherence interfere study result . 7 . ) Nonadherence efavirenz therapy ( regularly miss great 1 dose/week ) 8 . ) Positive pregnancy test breastfeed female . 9 . ) Severe potentially lifethreatening adverse event/toxicitiy efavirenz , administration additional dose efavirenz would unsafe deem unwarranted study personnel patient 's primary physician .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>May 20, 2008</verification_date>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Cytochrome P450</keyword>
	<keyword>HIV Resistance</keyword>
	<keyword>Drug Interaction</keyword>
	<keyword>Non-Nucleoside Reverse Transcriptase Inhibitors</keyword>
	<keyword>HIV Positive</keyword>
	<keyword>Healthy Volunteer</keyword>
	<keyword>HV</keyword>
</DOC>